Alexander Sparre-Ulrich
Chief Executive Officer at Antag Therapeutics ApS
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kirsten Drejer | M | 68 |
Antag Therapeutics ApS
 Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | - |
| Jens Juul Holst | M | - |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | 7 years |
| Anker Gunvald Lundemose | M | 63 |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | - |
| Emmanuelle Coutanceau | M | 44 |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | - |
| Christine T. Fischette | M | - |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | 3 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexander Sparre-Ulrich
- Personal Network
